S t a m p s
C o m m e m o r a t in g M
e d ic in e
“ M a la ria ” JO SEPH AGRIS, M .D ., D.D.S. stam p illustrated was used to publicize the world-wide campaign to irradicate malaria. Malaria is an ancient disease that instantly brings to mind the Orient, Africa and Central and South America. Most people do not realize that it once was a scourge in the United States too, particularly in the southern states. It is a little known fact that in 1835 some 6 million cases of malaria were reported in the southern part of our country. Long ago the United States devoted money, time, and talent to a successful malaria irradication program in the southern states. Today, fewer than 50 cases are found here each year, and most of these are contracted outside the United States. The design o f this stam p features the great seal of the U .S.A . and an adaptation of the emblem of the World Health Organization (W HO). The W HO seal is a dark shade of blue against the lighter blue of the stam p itself. The great seal of the United States is ochre against a circular white background. The stamp m easures somewhat less than one inch in height and somewhat less than one and one-half inches in width. It was printed on the Giori press, an early multi-color printer, and issued in panes o f 50. The first stam ps were placed on sale in Washington D.C. on March 30, 1962. Many countries around the world have used stam ps to publicize their struggles against malaria. In fact, there have been enough stam ps issued depicting vari ous aspects o f the fight against malaria to make stam p collection on this subject a specialization in itself.
The
F I G U R E 1. Dr. Agris is In structor in Plastic Surgery, Departm ent o f Surgery, Baylor College o f Medicine, H ouston, Texas.
674
J. Dermatol. Surg. Oncol. 4:9 Septem ber 1978
SYNALAR
(fluocinolone acetonide) CREAM 0.025%. 0.01% OINTMENT 0.025% SOLUTION 0.01% SYNEMOL Cream 0.025% SYNAIAR-HP Cream 0.2% Description Synalar* Synemol* and Synalar-HP® contain the steroid fluocinolone acetonide. Their chemical name is 6a. 9a-difluoro-16a-hydroxyprednisolone-16,17-acetonide. Synalar cream contains fluocinolone acetonide 0.25 mg./g. or 0.1 m g./g in a water-washable aqueous base of stearic acid, propylene glycol, sorbltan monostearate and monooleate. polysorbate 60, purified water and citric acid with methylparaben and propylparaben as preservatives Synalar ointment contains fluocinolone acetonide 0.25 mg,/g. in a white petrolatum U.S.P vehicle. Synalar solution contains fluocinolone acetonide 0.1 mg./ml. in a water-washable base of propylene glycol with citric acid. Synemol cream contains fluocinolone acetonide 0.25 mg./g. In a water-washable aqueous emollient base of stearyl alcohol, cetyl alcohol, mineral oil. propylene glycol, sorbltan monostearate, polysorbate 60, purified water and citric acid. Synalar-HP cream contains fluocinolone acetonide 2 mg./g In a water-washable aqueous base of stearyl alchol, cetyl alcohol, mineral oil. propylene glycol, sorbltan monostearate, polysorbate 60, purified water and citric acid with methylparaben and propylparaben as preservatives. Indications Inflammatory manifestations of cortlcosferoidresponslve dermatoses. Contraindications Topical steroids are contraindicated in patients with a history of hypersensitivity to any of the components of the preparation. SYNALAR-HP* (fluocinolone acetonide) 0.2% cream should not be used on Infants up to two years of age Precautions If Irritation develops, discontinue the product and Institute appropriate therapy. In presence of an Infection Institute use of an appropriate antlfungal or antibacterial agent. If a favorable response does not occur promptly, discontinue the corticosteroid until the infection has been adequately controlled. If extensive areas are treated or If occlusive technique Is used, there will be Increased systemic absorption of the corticosteroid and suitable precautions should be taken, particularly In children and Infants. The safety of topical steroids In pregnant women has not absolutely been established. In laboratory animals, increases In Incidences of fetal abnormalities have been associated with exposure of gestatlng females to topical corticosteroids. In some cases at rather low dosage levels. Therefore, drugs of this class should not be used extensively on pregnant patients. In large amounts or for prolonged periods of time. These products are not for ophthalmic use SYNALAR-HP cream should not be used for prolonged periods and the quantify per day should not exceed 2 g. of formulated material. Adverse Reactions Local adverse reactions reported with topical corticosteroids: burning. Itching, Irritation, dryness, folliculitis, hypertrichosis, acneform eruptions, hypopigmentatlon, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary Infection, skin atrophy, striae, miliaria. How Supplied Synalar* (fluocinolone acetonide) Cream 0.025% —15 and 60g. tubes and 120 and 425g jars. Cream 0.01% —15. 45 and 60g. tubes and 120 and 425g. jars. Ointment 0.025% -1 5 and 60g. tubes and 425g. jars. Solution 0.01% —20 and 60cc. plastic squeeze bottles. Synemol* (fluocinolone acetonide) Cream 0.025% —15 and 60g. tubes. Synalar-HP* (fluocinolone acetonide) Cream 0.2% —12g. tubes.
C o m m e m o r a t in g M
e d ic in e
“ M a la ria ” JO SEPH AGRIS, M .D ., D.D.S. stam p illustrated was used to publicize the world-wide campaign to irradicate malaria. Malaria is an ancient disease that instantly brings to mind the Orient, Africa and Central and South America. Most people do not realize that it once was a scourge in the United States too, particularly in the southern states. It is a little known fact that in 1835 some 6 million cases of malaria were reported in the southern part of our country. Long ago the United States devoted money, time, and talent to a successful malaria irradication program in the southern states. Today, fewer than 50 cases are found here each year, and most of these are contracted outside the United States. The design o f this stam p features the great seal of the U .S.A . and an adaptation of the emblem of the World Health Organization (W HO). The W HO seal is a dark shade of blue against the lighter blue of the stam p itself. The great seal of the United States is ochre against a circular white background. The stamp m easures somewhat less than one inch in height and somewhat less than one and one-half inches in width. It was printed on the Giori press, an early multi-color printer, and issued in panes o f 50. The first stam ps were placed on sale in Washington D.C. on March 30, 1962. Many countries around the world have used stam ps to publicize their struggles against malaria. In fact, there have been enough stam ps issued depicting vari ous aspects o f the fight against malaria to make stam p collection on this subject a specialization in itself.
The
F I G U R E 1. Dr. Agris is In structor in Plastic Surgery, Departm ent o f Surgery, Baylor College o f Medicine, H ouston, Texas.
674
J. Dermatol. Surg. Oncol. 4:9 Septem ber 1978
SYNALAR
(fluocinolone acetonide) CREAM 0.025%. 0.01% OINTMENT 0.025% SOLUTION 0.01% SYNEMOL Cream 0.025% SYNAIAR-HP Cream 0.2% Description Synalar* Synemol* and Synalar-HP® contain the steroid fluocinolone acetonide. Their chemical name is 6a. 9a-difluoro-16a-hydroxyprednisolone-16,17-acetonide. Synalar cream contains fluocinolone acetonide 0.25 mg./g. or 0.1 m g./g in a water-washable aqueous base of stearic acid, propylene glycol, sorbltan monostearate and monooleate. polysorbate 60, purified water and citric acid with methylparaben and propylparaben as preservatives Synalar ointment contains fluocinolone acetonide 0.25 mg,/g. in a white petrolatum U.S.P vehicle. Synalar solution contains fluocinolone acetonide 0.1 mg./ml. in a water-washable base of propylene glycol with citric acid. Synemol cream contains fluocinolone acetonide 0.25 mg./g. In a water-washable aqueous emollient base of stearyl alcohol, cetyl alcohol, mineral oil. propylene glycol, sorbltan monostearate, polysorbate 60, purified water and citric acid. Synalar-HP cream contains fluocinolone acetonide 2 mg./g In a water-washable aqueous base of stearyl alchol, cetyl alcohol, mineral oil. propylene glycol, sorbltan monostearate, polysorbate 60, purified water and citric acid with methylparaben and propylparaben as preservatives. Indications Inflammatory manifestations of cortlcosferoidresponslve dermatoses. Contraindications Topical steroids are contraindicated in patients with a history of hypersensitivity to any of the components of the preparation. SYNALAR-HP* (fluocinolone acetonide) 0.2% cream should not be used on Infants up to two years of age Precautions If Irritation develops, discontinue the product and Institute appropriate therapy. In presence of an Infection Institute use of an appropriate antlfungal or antibacterial agent. If a favorable response does not occur promptly, discontinue the corticosteroid until the infection has been adequately controlled. If extensive areas are treated or If occlusive technique Is used, there will be Increased systemic absorption of the corticosteroid and suitable precautions should be taken, particularly In children and Infants. The safety of topical steroids In pregnant women has not absolutely been established. In laboratory animals, increases In Incidences of fetal abnormalities have been associated with exposure of gestatlng females to topical corticosteroids. In some cases at rather low dosage levels. Therefore, drugs of this class should not be used extensively on pregnant patients. In large amounts or for prolonged periods of time. These products are not for ophthalmic use SYNALAR-HP cream should not be used for prolonged periods and the quantify per day should not exceed 2 g. of formulated material. Adverse Reactions Local adverse reactions reported with topical corticosteroids: burning. Itching, Irritation, dryness, folliculitis, hypertrichosis, acneform eruptions, hypopigmentatlon, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary Infection, skin atrophy, striae, miliaria. How Supplied Synalar* (fluocinolone acetonide) Cream 0.025% —15 and 60g. tubes and 120 and 425g jars. Cream 0.01% —15. 45 and 60g. tubes and 120 and 425g. jars. Ointment 0.025% -1 5 and 60g. tubes and 425g. jars. Solution 0.01% —20 and 60cc. plastic squeeze bottles. Synemol* (fluocinolone acetonide) Cream 0.025% —15 and 60g. tubes. Synalar-HP* (fluocinolone acetonide) Cream 0.2% —12g. tubes.
